Download
jca.21889.pdf 3,64MB
WeightNameValue
1000 Titel
  • Rapid development of a de novo convalescent plasma program in response to a global pandemic: A large southeastern U.S. blood center's experience
1000 Autor/in
  1. Reik, Rita |
  2. Gammon, Richard |
  3. Carol, Nancy |
  4. Smith, Judith |
  5. Grable, Martin |
  6. Forbes, Susan |
  7. Wu, Yanyun |
  8. Reed, Lance |
  9. Rogers, Michael |
  10. Prichard, Alicia |
  11. Paul, Scott |
  12. Scholl, George |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-01
1000 Erschienen in
1000 Quellenangabe
  • Early View
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1002/jca.21889 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: During the pandemic in the spring of 2020 with no vaccine or treatment for SARS‐CoV‐2 and its associated disease, COVID‐19, convalescent plasma from recovered COVID‐19 (CCP) patients offered a potential therapy. In March 2020, the United States (U.S.) Food and Drug Administration (FDA) authorized CCP under emergency Investigational New Drug (eIND) exemption and an IRB‐approved Expanded Access Program (EAP) to treat severe COVID‐19. Hospital demand grew rapidly in the Southeastern U.S., resulting in backlogs of CCP orders. We describe a large U.S. blood center's (BC) rapid implementation of a CCP program in response to community needs. STUDY DESIGN AND METHODS: From April 2 to May 17, 2020, CCP was collected by whole blood or apheresis. Initial manual approaches to donor intake, collection, and distribution were rapidly replaced with automated processes. All CCP donors and products underwent FDA‐required screening and testing. RESULTS: A total of 619 CCP donors (299 females, 320 males) presented for CCP donation (161 [25.7%] whole blood, 466 [74.3%] plasmapheresis) resulting in 1219 CCP units. Production of CCP increased as processes were automated and streamlined, from a mean of 11 donors collected/day for the first month to a mean of 25 donors collected/day in the subsequent 2 weeks. Backlogged orders were cleared, and inventory began to accumulate 4 weeks after project initiation. CONCLUSION: The BC was able to implement an effective de novo CCP collection program within 6 weeks in response to a community need in a global pandemic. Documentation of the experience may inform preparedness for future pandemics.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal antibodies
lokal blood donors
lokal hemapheresis technology
lokal recruitment
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UmVpaywgUml0YQ==|https://orcid.org/0000-0002-1175-9579|https://frl.publisso.de/adhoc/uri/Q2Fyb2wsIE5hbmN5|https://frl.publisso.de/adhoc/uri/U21pdGgsIEp1ZGl0aA==|https://frl.publisso.de/adhoc/uri/R3JhYmxlLCBNYXJ0aW4=|https://frl.publisso.de/adhoc/uri/Rm9yYmVzLCBTdXNhbg==|https://frl.publisso.de/adhoc/uri/V3UsIFlhbnl1bg==|https://frl.publisso.de/adhoc/uri/UmVlZCwgTGFuY2U=|https://frl.publisso.de/adhoc/uri/Um9nZXJzLCBNaWNoYWVs|https://frl.publisso.de/adhoc/uri/UHJpY2hhcmQsIEFsaWNpYQ==|https://frl.publisso.de/adhoc/uri/UGF1bCwgU2NvdHQ=|https://frl.publisso.de/adhoc/uri/U2Nob2xsLCBHZW9yZ2U=
1000 Label
1000 Förderer
  1. U.S. Food and Drug Administration |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer U.S. Food and Drug Administration |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6427117.rdf
1000 Erstellt am 2021-04-29T10:18:25.322+0200
1000 Erstellt von 218
1000 beschreibt frl:6427117
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Mon May 31 12:33:34 CEST 2021
1000 Objekt bearb. Mon May 31 12:33:16 CEST 2021
1000 Vgl. frl:6427117
1000 Oai Id
  1. oai:frl.publisso.de:frl:6427117 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source